NANOFS Stock Overview
Engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Nanoform Finland Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.10 |
| 52 Week High | €37.50 |
| 52 Week Low | €12.42 |
| Beta | 0.79 |
| 1 Month Change | -22.61% |
| 3 Month Change | -22.87% |
| 1 Year Change | -24.19% |
| 3 Year Change | -79.33% |
| 5 Year Change | n/a |
| Change since IPO | -71.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| NANOFS | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -0.7% | 1.1% | -0.1% |
| 1Y | -24.2% | 14.6% | 3.7% |
Return vs Industry: NANOFS underperformed the Swedish Life Sciences industry which returned 16.5% over the past year.
Return vs Market: NANOFS underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| NANOFS volatility | |
|---|---|
| NANOFS Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: NANOFS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: NANOFS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Edward Haeggstrom | www.nanoform.com |
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj Fundamentals Summary
| NANOFS fundamental statistics | |
|---|---|
| Market cap | SEK 1.21b |
| Earnings (TTM) | -SEK 266.07m |
| Revenue (TTM) | SEK 27.99m |
43.3x
P/S Ratio-4.6x
P/E RatioIs NANOFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOFS income statement (TTM) | |
|---|---|
| Revenue | €2.43m |
| Cost of Revenue | €521.04k |
| Gross Profit | €1.91m |
| Other Expenses | €24.98m |
| Earnings | -€23.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 78.54% |
| Net Profit Margin | -950.53% |
| Debt/Equity Ratio | 0% |
How did NANOFS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:01 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanoform Finland Oyj is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Sami Sarkamies | Danske Bank |
| Christian Glennie | Stifel, Equities Research |